Apex Biotechnology Corp. · TWSE:1733
Apex Biotechnology — Investor Conference 2022
15 slides from Apex Biotechnology's conference presentation, Nov 17, 2022
Slide 1: 2022 3Q Investor Conference
BYE 2h APEXBIO aiwan 2022 3Q APEXBIO
Slide 2: Company profile
Company profile Stock # TSEC 1733 Industry IVD Medical Device • Head quarter: No. 7, Li-Hsin 5th Rd., Hsinchu Science Park, Hsinchu, Taiwan Operation • Tao Yuan Factory: No. 180, Lane 70, Wuqing Rd., Dayuan Dist., Locations Taoyuan City 337, Taiwan • Suzhou Corp.: Room 106, No.2, Kecheng Road, SIP,
Slide 3: Milestone
Milestone 2007 Lactate launch 2017 Acquired Omnis Health LLC 1997 ApexBio set-up 2008 Voice BGM launch Brazil ANVISA notified 1998 BGM FDA 510K approval 2009 Taoyuan factory set-up 2018 ivCGM production set-up 1999 Uric Acid patent granted 2010 Tele-health tech build-up Ket-1 FDA 510K approval 2000
Slide 4: Quality system
Quality system Region The Authority Regulatory compliance Taiwan TFDA GMP ISO 13485:2016 EU CE CE mark number:CE0197 EN ISO 15197:2015 510K’s USA FDA FDA on-site audit w/o 483 citations 2001/2006/2011/2016 China CFDA Medical Device Class II Japan PMDA Brazil ANVISA 2017 passed on-site audit
Slide 5: ESH policy
ESH policy In response to environmental protection and occupational safety and health policies, management procedures have been established year by year to consistently comply with the GRI guidelines in order to achieve the goal of sustainable of enterprises.
Slide 6: Product portfolio
Product portfolio Blood glucose monitoring systems Professional Monitoring systems Uric Acid Hemoglobin Lactate Ketone HbA1C Multi-functional systems Glucose + Uric Acid Glucose + Ketone Glucose +Cholesterol Glucose+Cholesterol+ TG+Uric Acid
Slide 7: GLUCOSURE POC
GLUCOSURE POC Glucose/Ketone POC barcode scanner + wifi Ketone POC barcode scanner + wifi (EU territory distributed by Roche ) Hospital
Slide 8: Eclipse PLUS
Eclipse PLUS For Clinic and Hospital Pre-screening Diabetic Kidney Disease
Slide 9: Customized projects
Customized projects Product platform focus on electrochemistry/photometry/ Lateral flow assay; developing a first tool of the world that can monitor liver function test for an ODM customer, and the product had been approved by TFDA in 2022 and published in Analytical and Bioanalytical Chemistry. s
Slide 10: New pipeline products
New pipeline products Continuous Glucose monitoring system (CGM) Lipid panel monitoring system Rapid test – Flu A/B test 、Vector-borne disease test and Economic animal and animal quarantine test
Slide 11: Global sales distribution
Global sales distribution Territory 2020 2021 2022/1-3Q America 42% 43.5% 41% EU 46% 45% 49% Asia 11% 11% 9% Africa 1% 0.5% 1%
Slide 12: Finance Performance
Finance Performance 2020 2021 2022/1-3Q Revenue 2,005,337 2,131,656 1,735,537 Gross margin 452,224 571,512 418,971 Operation profit 103,328 204,949 125,879 Profit after tax 94,629 202,289 138,582 EPS 0.95 2.03 1.39 G/M ratio 22% 27% 24% Shipped Meter Qty (kit) 1,731K 1,677K 1,471K Shipped Strip Qty(
Slide 13: Product ratio
Product ratio 2021 2022/ 1-3Q BGM & A1C Electrode BGM & A1C Electrode Non-BGM Others Non-BGM Others 4% 4% 10% 15% 15% 12% 71% 71% Non-BGM Hemoglobin/Ketone/UricAcid/Lactate/Cholesterol/ Pesticide quick check etc
Slide 14: Corporate Governance Evaluation (2021)
th the 8 Corporate Governance Evaluation (2021) Number of Points for Total number inapplicable Extra Credit Category weighting satisfied of indicators indicators Indicators: indicators Year 2020 2021 2020 2021 2020 2021 2020 2021 2020 2021 Protecting Shareholder Rights and Interests and Treating Sha
Slide 15: Thank you
Thank you APEXBIO